Dr Tom Ashdown

Dr Tom Ashdown is Medical Director at Richmond Pharmacology, providing medical leadership across early-phase clinical trials from first-in-human through to Phase III studies. He oversees the safe and effective delivery of complex clinical research across a broad range of therapeutic areas, ensuring the highest standards of participant safety, scientific integrity and regulatory compliance.

Tom joined Richmond Pharmacology in 2021 as a Specialty Research Physician and has progressed through successive medical leadership roles to become Medical Director. He has extensive experience supporting studies evaluating innovative therapies, including gene editing, RNA-targeted medicines and novel immunological treatments.

A board-certified Pharmaceutical Medicine Consultant, Tom completed Pharmaceutical Medicine Specialty Training (PMST) and holds a BSc in Medical Pharmacology. Prior to joining Richmond, he trained in Trauma and Orthopaedic Surgery within the NHS, bringing valuable frontline clinical experience to early-phase medicine.

Alongside his leadership responsibilities, Tom has a strong interest in research and innovation, contributing to the advancement of early-phase clinical development and the evaluation of emerging therapeutic technologies.

At Richmond Pharmacology, Tom is committed to advancing innovative medicines through safe, scientifically rigorous clinical research, helping sponsors accelerate development while maintaining exceptional standards of participant care.

‍